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HeterodimerizationEpidermal growth factor (EGF) regulates normal and tumor cell proliferation via epidermal growth factor
receptor (EGFR) phosphorylation, homo- or heterodimerization and activation of mitogen-activated protein
kinases (MAPKs) and PI3K/AKT cell survival pathways. In contrast, SST via activation of ﬁve different receptor
subtypes inhibits cell proliferation and has been potential target in tumor treatment. To gain further insight
for the effect of SSTRs on EGFR activated signaling, we determine the role of SSTR1 and SSTR1/5 in human
embryonic kidney (HEK) 293 cells. We here demonstrate that cells transfected with SSTR1 or SSTR1/5
negatively regulates EGFmediated effects attributed to the inhibition of EGFR phosphorylation, MAPKs as well
as the cell survival signaling. Furthermore, SSTR effects were signiﬁcantly enhanced in cells when EGFR was
knock down using siRNA or treated with selective antagonist (AG1478). Most importantly, the presence of
SSTR in addition to modulating signaling pathways leads to the dissociation of the constitutive and EGF
induced heteromeric complex of EGFR/ErbB2. Furthermore, cells cotransfected with SSTR1/5 display
pronounced effect of SST on the signaling and dissociation of the EGFR/ErbB2 heteromeric complex than
the cells expressing SSTR1 alone. Taken together this study provides the ﬁrst evidence that the presence of
SSTR controls EGF mediated cell survival pathway via dissociation of ErbB heteromeric complex. We propose
that the activation of SSTR and blockade of EGFR might serve novel therapeutic approach in inhibition of
tumor proliferation.FR, epidermal growth factor
; GPCRs, G-protein coupled
PK, mitogen-activated protein
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The members of receptor tyrosine kinases (RTKs) and G-protein
coupled receptors (GPCRs) family constitute themajor components of
cell membrane and elicit diverse pharmacological and physiological
roles upon agonist activation. Epidermal growth factor (EGF)
promotes cell growth and proliferation through its four receptors
commonly known as ErbB1–4. ErbB1, also known as EGFR, is the key
regulator of intracellular signaling mechanism of ligand EGF [1,2].
EGFR is activated by EGF as well as other related ligands containing an
EGF like domain [3]. Ligand binding induces receptor phosphorylation,homo- and heterodimerization with the composition of the ligand/
receptor complex and is involved in regulation of downstream
signaling pathways. EGFR mediated signaling has a key role in cell
proliferation promoting tumor growth. Amongst them are the
mitogen-activated protein kinase (MAPK) and phosphatidylinositol-
3-protein kinase (PI3K)/AKT pathways. Activation of the former is
generally associated with increased proliferation while the latter
regulates cell survival. To this end, multiple studies have reported that
EGFR and ErbB2 over-expression are commonly associated with poor
prognosis and failure to respond to hormonal therapy [4,5]. The fact
that over- and co-expression of ErbBs in various tumor tissues is
associated with tumor progression is undisputed but the exact
mechanisms contributing to tumor growth and proliferation remain
elusive [6–8].
Somatostatin (SST) is a growth hormone inhibitory peptide which
is widely expressed and exerts different functions in tissue speciﬁc
manner. In addition to its signiﬁcant physiological functions, SST and
its analogues serve as potential anti-tumor drugs, however not
convincing yet clinically [9–13]. SST effects are mediated via ﬁve
different receptor subtypes (SSTR1–5) belonging to seven transmem-
brane GPCRs family. SSTRs have been well characterized and display
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including human breast cancer, pancreatic, pituitary, neuroblastoma
and glioma cells have been shown positive for SSTRs [11,15,16,18].
Recent studies have described that SSTRs exhibit homo-and hetero-
dimerization and dissociation of preformed dimers in response to
agonist treatment in receptor-speciﬁcmanner [19–26]. SSTRs not only
heterodimerize within the family but also with other GPCRs as well as
RTKs that result in different effects on signaling properties than the
native receptors [19,20,22–24,27]. Given the widespread distribution
of SSTRs, all the 5 receptor subtypes upon activation with SST or
receptor-speciﬁc agonists regulate various signaling enzymes includ-
ing adenylyl cyclase, guanylyl cyclase and phosphotyrosine phospha-
tases along with modulation of ion conductance channels [28–35].
Importantly, unlike ErbBs, the anti-proliferative effect of SSTRs is
executed by the activation and/or inhibition of mitogen-activated
protein kinases (MAPKs) and PI3K/AKT in cell and tissue speciﬁc
manner [28–35].
Over the years, it has been evident that GPCRs and RTKs stimulate
common downstream signaling molecules with distinct physiological
responses of cells. Also, cross-talk between these receptor families has
been characterized with respect to their roles in several disease states
[23,36,37]. GPCR agonists such as endothelin (ET-1), lysophosphatidic
acid (LPA) and thrombin have been shown to induce phosphorylation
of EGFR via a process known as transactivation and are associated
with MAPK activation in both transformed and non-transformed cells
[38–40]. ErbBs regulate the PI3K/AKT pathway associated with tumor
growth and account for poor therapeutic response [41,42]. Inactiva-
tion of EGFR provides potential therapeutic intervention in cell
proliferation and tumor growth [43]. In some tumor cells, such as
pancreatic tumor cells, SST antagonized EGF mediated mitogenic
effects probably via activation of phosphotyrosine phosphatase (PTP)
[44]. In human breast cancer cells, i.e., MCF-7 and MDA-MB-231, SSTR
and ErbB subtypes exhibit colocalization suggesting possible func-
tional interaction between these receptor subtypes [16]. Our recent
study using MCF-7 and MDA-MB-231 breast cancer cells demonstrat-
ed that EGF induced EGFR phosphorylation is associated with the
recruitment of key adaptor proteins such as Shc, Grb, son of sevenless
(SOS) and SH2 domain-containing phosphatases (SHP1) and the
activation of these adaptor proteins is SSTR1 or 5 dependent [23].
Since all SSTR and ErbB subtypes are endogenously expressed in
human breast cancer cell lines, this poses a potential pitfall in
delineating the interactions between individual SSTRs and ErbBs.
Our previous studies have also described the time dependent
internalization of SSTR subtypes in response to SST treatment [45].
SSTR1 is the only subtype that upregulated at the cell surface upon
agonist treatment, whereas SSTR5 is internalized. Interestingly, cells
cotransfected with SSTR1/5 displayed SSTR1 internalization [25]. We
have recently described that SSTR5 inhibits EGFR phosphorylation and
consequently modulates EGF mediated signaling pathways. Further-
more, SSTR5 dissociated the heterodimerization of EGFR/ErbB2 [46].
Whether internalization resistant SSTR1 with or without SSTR5
modulates the expression pattern of EGFR is currently unknown.
Most importantly, SST mediated inhibition of cell proliferation or cell
survival signaling cascades and induction of apoptosis in receptor-
speciﬁc manner interfering in EGF mediated signaling has not been
studied yet. Accordingly, in the present study, we determined the
functional interactions between SSTR and ErbB subtypes in HEK293
cells expressing ErbBs endogenously [47] and stably transfected with
SSTR1 and SSTR1/5. Furthermore, in support of our data, the EGFR
receptor antagonist AG1478 and EGFR small interference RNA (siRNA)
were used to determine whether downregulation of EGFR enhanced
the SST effect. The results presented here provide novel insights, at the
molecular and cellular levels, for the role of SSTR subtypes in
modulation of the EGFR mediated tumorigenic signaling pathways
responsible for the poor prognosis and failure of chemo/hormonal
therapy.2. Materials and methods
2.1. Materials
Somatostatin (SST-14) was obtained from Bachem (Torrance,
CA). SSTR1 and SSTR5 speciﬁc non-peptide agonists L-797,591 and
L-817,818 were kindly provided by Dr. Rohrer from Merck & Co [48].
EGFR inhibitor, AG1478 and protein A/G-agarose beads were
purchased from Calbiochem (San Diego, CA). Speciﬁc antibodies
against phospho- and total EGFR, ERK1/2, ERK5, p38, PI3K and AKT
were obtained from Cell Signaling Technology (MA, USA). Mouse
monoclonal and/or rabbit polyclonal antibodies against EGFR, ErbB2
and p27Kip1 were acquired from Santa Cruz Biotechnology (Santa
Cruz, CA). Mouse monoclonal antibody against PTP1C was obtained
from BD Biosciences (Mississauga, ON). Horseradish peroxidase-,
ﬂuorescein- and Cy3-conjugated secondary antibodies were
obtained from Jackson ImmunoResearch, (West Grove, PA). Human
epidermal growth factor (hEGF), mouse monoclonal or rabbit
polyclonal antibodies against cMyc, HA and β-actin were obtained
from Sigma Aldrich Inc. (St. Louis, MO). Goat anti-mouse and goat
anti-rabbit Alexa Fluor-488 and Alexa Fluor-594 were purchased
from Invitrogen (Burlington, ON). Chemiluminescent ECL detection
system and nitrocellulose Hy-Bond membrane were obtained from
Amersham Ltd. (Oakdale, ON). Lipofectamine transfection reagent
was purchased from BIO-RAD Laboratories (Mississauga, ON).2.2. Cell lines and culture
The HA-SSTR1 and cMyc-SSTR5 constructs were prepared using
pCDNA3.1/Neo (neomycin resistant) or pCDNA3.1/Hygro vector
(hygromycin resistant), respectively, as described earlier [26]. Stable
transfections of HEK293 cells expressing HA-SSTR1 or both HA-SSTR1/
cMyc-SSTR5 (SSTR1/5) were prepared by Lipofectamine transfection
reagent as previously described [26]. SSTR1 monotransfected cells
were maintained in Dulbecco's MEM (DMEM) supplemented with
700 μg/ml neomycin and 10% fetal bovine serum (FBS). Cotransfected
cells were maintained in DMEM supplemented with both 700 μg/ml
neomycin and 400 μg/ml hygromycin as previously described [26]. In
cells stably transfected with SSTR1 or SSTR1/5, the receptor
expression was 250–300 fmol/mg protein, respectively.2.3. Immunocytochemistry
Receptor expression and colocalization was studied using indirect
immunoﬂuorescence immunocytochemistry as described earlier
[22,23]. wt and cells transfected with SSTR1 or SSTR1/5 were grown
on poly-D-lysine coated coverslips in 24-well plates. Brieﬂy, cells were
treated with SST (1 μM) or EGF (1nM) alone and in combination for
15 min at 37 °C. Additionally, cells were also treated with SSTR1 or
SSTR5 speciﬁc agonists L-797,591 (10 nM) or L-817,818 (10 nM),
respectively, for 15 min at 37 °C. Following treatment, cells were ﬁxed
with 4% paraformaldehyde for 20 min and following three subsequent
washes cells were incubated in 5% normal goat serum (NGS) for 1 h.
Cells were then incubated with poly- or monoclonal antibodies
against EGFR (1:500) and ErbB2 (1:500), HA (1:500) and cMyc
(1:500) overnight at 4 °C. Anti- HA and cMyc antibodies were used to
detect SSTR1 and SSTR5 expression, respectively. Cells were then
incubated with goat-anti-mouse or rabbit secondary antibodies
conjugated with Alexa Fluor-488 (1:700) or Alexa Fluor-594
(1:1200) for 1 h at RT. The coverslips were mounted onto glass slides,
viewed and photographed using Leica DMLB microscope attached to
Retiga 2000R camera. NIH ImageJ software and Adobe Photoshop (San
Jose, CA) were used to create merged images and composites,
respectively.
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Western blot analysis was performed to determine the expression
of signalingmolecules in cell extracts prepared fromwt and cells stably
transfected with SSTR1 or cotransfected with SSTR1/5 as previously
described [22]. Brieﬂy, cells were treated with SST (1 μM) or EGF
(1nM) alone and in combination for 0, 5, 10, 20, and 40 min at 37 °C. In
additional experiments cells were treated with EGFR antagonist
AG1478 (10 nM) in the presence or absence of SST, EGF, SSTR1 or
SSTR5 speciﬁc agonists L-797,591 (10 nM) or L-817,818 (10 nM) for
15 min at 37 °C. Cells were lysed using radio-immune precipitation
assay (RIPA) buffer containing 150 mM NaCl, 50 mM Tris–HCl, 1%
Nonidet P-40, 0.1% SDS, 0.5% sodium deoxycholate, pH 8.0. Total
protein (15 μg) was fractionated on a 10% SDS-polyacrylamide gel and
transferred onto the nitrocellulose Hy-Bond ECL membrane. The
membrane was blocked with 5% non-fat dry milk and incubated with
primary antibodies against phosphorylated and total EGFR, ERK1/2,
ERK5, p38, PI3K and AKT (1:1000). The detection of bands was
performed using chemiluminescence as per the manufacturer's
instructions (Amersham Biosciences). Images were captured using
an Alpha Innotech FluorChem 8800 gel box imager and bands
quantiﬁed using FluorChem software. β-Actin was used as the loading
control.
To determine the changes in p27Kip1 expression, wt and cells
expressing SSTR1 or SSTR1/5 were serum deprived for 24 h and
followed by treatment with SST, EGF and SST+EGF and subsequently
subjected to 10% SDS-PAGE. Themembranes were probedwithmouse
monoclonal anti-p27Kip1 antibody (1:500) overnight at 4 °C. To
determine the expression of phosphotyrosine phosphatases (PTP),
cell membrane and cytosolic extracts from wt, SSTR1 and SSTR1/5
transfected cells were prepared as previously described [23]. Brieﬂy,
cells were treated with SST (1 μM), EGF (1nM) and SST+EGF for
30 min at 37 °C. Cell pellets were homogenized in 20 mM Tris–HCl
buffer containing 0.32 M sucrose and 2.5 mM dithiothreitol (DTT), pH
7.5. The homogenate was then centrifuged at 1000 rpm and the
supernatant obtained was further centrifuged at 10000 rpm for
45 min. Membrane and cytosolic fractions were subjected to 10%
SDS-PAGE, and themembranes were probed usingmousemonoclonal
anti-PTP1C antibody (1:500).
2.5. siRNA construct
The plasmid pSilencer 4.1 CMV neo (Ambion) was prepared by
inserting a hEGFR shRNA coding sequence made by oligonucleotides
annealing using BamH1 and Hind III restriction sites. The targeted
sequence is 1616–1634.wt or cells transfected with SSTR1 and SSTR1/
5 were transiently transfected with the EGFR siRNA (2 μg) for 36 h.
Cells were subsequently treated with SST (1 μM), EGF (1nM), SST+
EGF, SSTR1 or SSTR5 speciﬁc agonists (L-797,591 or L-817,818;
10 nM, respectively) for 15 min at 37 °C. Cell lysates were subjected to
Western blot analysis to determine the status of phospho- and total
EGFR, ERK1/2, p38, PI3K and AKT, respectively. Mismatched siRNA
was used as a negative control.Fig. 1. Expression of SSTR1, SSTR5, EGFR and ErbB2 inwt, SSTR1 and SSTR1/5 transfected HEK
or EGF (1 nM) alone and in combination for 15 min at 37 °C. Total membrane protein (15 μg)
Materials and methods section. The nitrocellulose membranes were probed with anti-EGFR
showing the expression of EGFR in membrane preparation of wt cells. EGFR expression was
upon treatment with EGF alone or in combination with SST in wt cells (*, Pb0.05 vs. contr
The expression of EGFR was decreased upon SST and remained unchanged in presence
(C) Immunoblots depicting the expression of EGFR in SSTR1/5 cotransfected cells. Note the ex
EGF alone or in combination with SST. (D–F) Conversely, the expression of ErbB2 remaine
transfected cells, the expression of SSTR1 was decreased but not signiﬁcantly upon treatme
(H) In cells transfected with SSTR1/5, the expression levels of SSTR1 were signiﬁcantly decrea
while SST alone was without any effect. (I) The expression of SSTR5 remained unchanged
depicted in histograms was quantiﬁed using densitometric analyses and normalized using β-
expression was not detected in wt cells (data not shown).2.6. Co-immunoprecipitation (co-IP)
wt and cells stably transfected with SSTR1 and SSTR1/5 were
treated with SST (1 μM) or EGF (1 nM), and SST+EGF for 15 min at
37 °C. Total membrane protein (200 μg) was solubilized in 1 ml RIPA
buffer for 1 h at 4 °C as described earlier [49]. Samples were incubated
with anti-EGFR antibody (1:200) for immunoprecipitation and
puriﬁed with protein A/G-agarose beads overnight at 4 °C. Puriﬁed
proteins were subjected to 7% SDS-PAGE and probed for the
expression of SSTR1 and SSTR5 using anti-HA or anti-cMyc antibodies
(1:500), respectively, as described previously [49].
2.7. Microscopic photobleaching FRET analysis (pbFRET)
Microscopic pbFRET analysis was performed on wt and cells
transfected with SSTR1 and SSTR1/5 as previously described [49].
Cells were grown to 70% conﬂuency on glass coverslips and treated
with SST (1 μM), EGF (1nM), SST+EGF, SSTR1 or SSTR5 speciﬁc
agonists (L-797,591 or L-817,818; 10 nM, respectively) for 15 min at
37 °C. Following agonist treatment, cells were subjected to immuno-
cytochemistry as described earlier [46]. The donor and acceptor pairs
were created using ﬂuorescein (FITC) and Cy3-conjugated secondary
antibodies, respectively. The photobleaching decay was determined
for the plasma membrane regions expressing donor or donor+
acceptor on a pixel by pixel basis. Effective FRET efﬁciency (E) was
calculated from the photobleaching (pb) time constants of the donor
taken in the absence (D−A) and presence (D+A) of acceptor as
described earlier [49].
2.8. Statistical analysis
The data presented in this study was analyzed using appropriate
statistical analysis tests using GraphPad Prism 4.0. The data were
analyzed using both one-way or two-way ANOVA and the post hoc
Dunnett's or Bonferroni's test, respectively, were applied according to
the experimental conditions to compare the treatments. Signiﬁcant
statistical differenceswere taken at *Pb0.05. The results are expressed
as mean±SEM and represent three independent experiments
(n=3).
3. Results
3.1. The expression of EGFR and ErbB2 in HEK293 cells expressing SSTR1
or SSTR1/5
EGFR is well expressed in cell membrane preparation of wt cells at
the expected molecular size of N170 kDa. EGFR membrane expression
was enhanced upon treatment with EGF alone or in combination with
SST; however, receptor expression was unaffected upon SST treat-
ment alone in wt cells (Fig. 1A). In cells expressing SSTR1, EGFR
membrane expression was reduced upon treatment with SST but
remained comparable to the control following EGF treatment. The
expression of EGFR increased with the combined treatment; however,293 cells.wt and cells transfected with SSTR1 or SSTR1/5 were treated with SST (1 μM)
was fractionated on 7% SDS-PAGE and subjected toWestern blot analysis as described in
, ErbB2, HA (SSTR1) and cMyc (SSTR5) antibodies (1:500). (A) Western blot analysis
unaffected in presence of SST, whereas the expression levels of receptor was enhanced
ol). (B) Immunoblot showing the expression of EGFR in cells transfected with SSTR1.
of EGF. In comparison receptor expression tend to increase in combined treatment.
pression of EGFR signiﬁcantly decreases upon SST treatment alone without any effect of
d unaltered in wt as well as in cells transfected with SSTR1 or SSTR1/5. (G) In SSTR1
nt with SST or EGF alone but remained comparable to control in combined treatment.
sed upon treatment with EGF alone and in combination with SST (*, Pb0.05 vs. control),
in SSTR1/5 cotransfected cells across all indicated treatments. The receptor expression
actin as loading control. Results are expressed as mean±SEM (n=3). SSTR1 and SSTR5
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EGFR expression was signiﬁcantly decreased in cell expressing SSTR1/
5 upon treatment with SST and remained unchanged upon EGF
treatment, whereas in combined treatment receptor expression waslower without any signiﬁcant difference than the control (Fig. 1C).
Conversely, ErbB2 expression (N185 kDa) was unaffected with
agonist treatment in all cell lines (Fig. 1D–F). As shown in Fig. 1G,
cells expressing SSTR1 displayed decreased membrane expression of
Fig. 2. Colocalization between EGFR and ErbB2 is inhibited in the presence of SSTR1. Representative photomicrographs illustrating colocalization of EGFR with ErbB2 or SSTR1 in wt
and in cells transfected with SSTR1 (A–C). Cells were treated with SST (1 μM) or EGF (1 nM) and SST+EGF for 15 min at 37 °C. Subsequently, cells were ﬁxed and processed for
colocalization as described in Materials and methods. (A) In wt cells, EGFR/ErbB2 displayed strong colocalization at the cell membrane in control and EGF treated cells. Conversely,
cells transfected with SSTR1 displayed complete loss of membrane colocalization between EGFR/ErbB2 upon treatment as indicated (B). Note enhanced colocalization between
SSTR1/EGFR with SST and EGF alone or in combination in treatment speciﬁc manner (C). EGFR expression at cell surface was predominant in all treatment except in presence of SST
with relatively high expression of SSTR1. Arrows in representative photographs indicate colocalization whereas arrowheads indicate cells devoid of colocalization. Scale bar=5 μm.
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treatment receptor expression was similar to control. In cotransfected
cells, SSTR1 expressionwas decreased signiﬁcantly when treated with
EGF alone or in the presence of SST, although SST alone was without
any effect (Fig. 1H). Contrary to SSTR1, the expression of SSTR5 was
unaffected and remained comparable to control across all treatments
(Fig. 1I). These observations are possibly associated with receptor-
speciﬁc trafﬁcking and support the role of SSTRs in altering the cell
surface expression of ErbB subtypes.
Further, to support the Western blot analysis, indirect immuno-
ﬂuorescence immunocytochemistry was accomplished for double
labeled colocalization. EGFR and ErbB2 exhibited strong colocaliza-
tion at the cell surface of wt cells which was signiﬁcantly increased
upon EGF treatment (Fig. 2A). Importantly, in cells transfected with
SSTR1, a complete loss of membrane colocalization between EGFR
and ErbB2 was evident irrespective of the indicated agonist
treatment (Fig. 2B). While the colocalization between EGFR/ErbB2
diminished, strong colocalization between EGFR and SSTR1 wasobserved at the cell surface in SSTR1 transfected cells (Fig. 2C). In
addition, decreased expression of EGFR was seen upon SST
treatment in cells expressing SSTR1 due to the upregulation of
SSTR1. As shown in Fig. 3A, the cells cotransfected with SSTR1/5
displayed inhibition of colocalization between EGFR/ErbB2 with SST,
EGF or SST+EGF as well as with SSTR1 or SSTR5 speciﬁc agonist L-
797,591 and L-817,818, respectively. On the contrary, as shown in
Fig. 3B, SSTR1 and EGFR displayed strong membrane colocalization
in basal conditions that was decreased with EGF and SSTR1 speciﬁc
agonist L-797,591. The colocalization between SSTR1/EGFR upon
treatment with SST alone or in combination with EGF was similar to
the untreated cells (Fig. 3B). Cotransfected cells demonstrated
enhanced colocalization between SSTR5/EGFR when treated with
SST or SSTR5 speciﬁc agonist L-817,818 alone or in combination
with EGF, whereas EGF alone was without any effect and receptor
expression remained comparable to the control (Fig. 3C). Summa-
rizing these data, it is evident that the presence of SSTR subtypes
impaired ErbBs expression, colocalization, and trafﬁcking, indicating
Fig. 3. EGFR and ErbB2 colocalization was diminished in cells cotransfected with SSTR1/5. Representative photomicrographs illustrating the receptor-speciﬁc colocalization of EGFR
with ErbB2 and SSTR1 or SSTR5 in cells cotransfected with SSTR1/5. Brieﬂy, cells were treated with SST (1 μM) or EGF (1 nM) alone and in combination as well as with SSTR1 or SSTR5
speciﬁc agonists L-797,591 (10 nM) or L-817,818 (10 nM), respectively, for 15 min at 37 °C and processed for immunocytochemistry. (A) EGFR/ErbB2 colocalization at the cell
surface was signiﬁcantly decreased upon indicated treatments in cotransfected cells. (B) SSTR1/EGFR colocalization at the membrane decreased upon treatment with EGF and SSTR1
speciﬁc agonist L-797,591 in comparison to control cells displaying strong colocalization. The colocalization between SSTR1/EGFR upon treatment with SST alone or with EGF
remained comparable to the basal. (C) In comparison, the colocalization between SSTR5/EGFR in cotransfected cells enhanced upon treatment with SST or SSTR5 speciﬁc agonist L-
817,818 alone or in combination with EGF when compared to basal. However, SSTR5/EGFR colocalization upon treatment with EGF alone remained comparable to control cells.
Arrowheads in the representative panels indicate loss of colocalization, while arrows indicate colocalization between receptor subtypes. Scale bar=5 μm.
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signaling cascades.
3.2. Somatostatin receptors inhibit EGFR phosphorylation
The duration of EGFR at the cell surface and receptor internaliza-
tion is associated with receptor phosphorylation. Accordingly, to
ascertain whether the status of EGFR phosphorylation (p-EGFR) is
modulated in the presence of SSTRs, time dependent effect of SST inthe presence or absence of EGF was determined. As shown in Fig. 4A,
in wt cells, EGF enhanced p-EGFR in a time dependent manner with
maximum phosphorylation at 10 and 20 min and later decreased at
40 min. The loss of EGFR phosphorylation at the later time point is
consistent with the observations showing that prolong ligand
activation induces EGFR internalization [50,51]. Furthermore, SST
alone was ineffective to induce any change in EGFR phosphorylation
but resulted in inhibition of EGF effect in combined treatment
(Fig. 4A). Examining the status of p-EGFR upon treatment with SST,
Fig. 4. The presence of SSTR1 or SSTR1/5 suppressed EGF mediated EGFR phosphor-
ylation. wt (A) and cells transfected with SSTR1 (B) or SSTR1/5 (C) were treated with
SST (1 μM) or EGF (1 nM) alone and in combination for indicated time points (0, 5, 10,
20 and 40 min) at 37 °C. Total protein (15 μg) was fractionated on 10% SDS-PAGE and
subjected to Western blot analysis as described in Materials and methods. The
membranes were probed with speciﬁc phospho- and total EGFR antibodies (1:1000).
EGFR phosphorylation remained comparable to 0 time upon treatment with SST. EGF
alone induced p-EGFR expression; however, following combined treatment with SST+
EGF, p-EGFR expression levels were not changed signiﬁcantly at any time points (A). In
cells expressing SSTR1, p-EGFR was signiﬁcantly abolished at all time points across all
treatments (B). Similarly, in SSTR1/5 cotransfected cells, p-EGFR was signiﬁcantly
diminished upon treatment with EGF alone andwith SST. However, upon SST treatment
p-EGFR remained comparable to 0 time. Densitometric analysis was performed to
quantify EGFR levels at indicated times after being normalized against the levels of total
EGFR or β-actin (not shown). *Pb0.05 indicates signiﬁcant comparison with 0 time
point in respective cell lines. The signiﬁcant changes between treatments of wt and
SSTR1 or SSTR1/5 transfected cells are indicated by #Pb0.05. Results are expressed as
mean±SEM, n=3. ND=not detected.
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loss of EGFR phosphorylation when compared to wt cells. Conversely,
cells transfected with SSTR1/5 displayed signiﬁcant inhibition of
p-EGFR upon treatment with EGF alone and in combination with
SST, whereas SST alone was without any discernable changes
(Fig. 4B and C). Importantly, the changes seen in the presence of
EGF alone or in combination with SST in cells transfected with
SSTR1 or SSTR1/5 were signiﬁcantly lower than the wt cells. These
observations are supporting evidence that the presence and the
activation of SSTR1 or both SSTR1/5 abrogate EGF stimulated EGFR
phosphorylation.
3.3. Changes in ERK-MAPK signaling in wt or cells expressing SSTRs are
receptor selective
EGF, like many other growth factors, activates various signal
transduction pathways including MAPKs and elicits cell proliferation
and differentiation. Accordingly, we next determined whether the
presence of SSTR1 or SSTR1/5 diverts EGF mediated extracellular
regulated protein kinase (ERK1/2) and ERK5 phosphorylation (Figs. 5
and 6). In wt cells, ERK1/2 was phosphorylated in a time dependent
manner upon agonist treatments. ERK1/2 phosphorylation enhanced
at early time and gradually decreased at later time points upon
treatments with SST or EGF alone and in combination (Fig. 5A).
Interestingly, in SSTR1 monotransfected cells, the phosphorylation of
ERK1/2 remained signiﬁcantly higher and sustained upon treatments
with SST and EGF either alone or combined when compared with
control (Fig. 5B). Similarly, in cotransfected cells expressing SSTR1/5,
the phosphorylation of ERK1/2 remained sustained at all time points
and indicated treatments; however, the expression levels of p-ERK1/2
were lower in comparison to wt and SSTR1 monotransfected cells
(Fig. 5C). These observations suggest that prolonged and sustained
phosphorylation of ERK1/2 upon activation of SSTRs is a requisite for
anti-proliferative effect similar to that described in CHO-K1 cells
[29,44]. These results indicate that both SST and EGF cause activation
of ERK1/2 with the distinct outcome on the cell proliferation.
Recently, ERK5, an analogous form of ERK, has been studied for its
regulatory cellular mechanisms and association with ErbBs in tumors
[52,53]. As shown in Fig. 6A, challenge of wt cells with EGF exhibits
enhanced ERK5 phosphorylation in a time dependent manner with
maximum phosphorylation at early time points which was decreased
at 40 min. When cells treated with SST alone or in combination with
EGF, ERK5 was phosphorylated at earlier time points and signiﬁcantly
decreased at later time points (Fig. 6A). Contrary to wt cells, SSTR1
transfected cells exhibited signiﬁcant decrease in ERK5 phosphoryla-
tion when treated with SST alone and with EGF, although, upon SST
treatment, p-ERK5 enhanced at 40 min but the effect was not
signiﬁcantly different in comparison to the control. This SST effect
was opposite to wt cells. However, upon EGF treatment alone, the
status of ERK5 phosphorylation remained comparable to the control
(Fig. 6B). In cotransfected cells, SST signiﬁcantly induced ERK5
phosphorylation in a time dependent manner, reaching maximum
activation by 10 min, whereas EGF mediated ERK5 phosphorylation
was signiﬁcantly enhanced in comparison to control but relatively
lower than SST alone (Fig. 6C). In contrast, SST effect was abolished
when cells were treated in combination. Consistent with our recent
study, these results suggest that SSTR1 might function differently in
mono- and/or cotransfected cells in modulation of ERK5 [46].
3.4. The presence of SSTRs inhibit EGF activated PI3K/AKT cell survival
signaling pathways
EGFR mediated cell proliferation and tumor growth is associated
with activation of the PI3K/AKT cell survival pathway and attributed
to hormonal treatment failure [54]. Accordingly, we determined the
effects of SST, EGF and SST+EGF on PI3K and AKT phosphorylation in
Fig. 5. SSTRs prolong the phosphorylation of ERK1/2 to exert anti-proliferative effect in
SSTR1 and SSTR1/5 transfected cells. wt and SSTR1 or SSTR1/5 transfected cells were
treated with SST (1 μM) or EGF (1 nM) and SST+EGF for 0, 5, 10, 20 and 40 min at 37 C.
Whole cell protein (15 μg) subjected to Western blot analysis and membranes were
processed for total and p-ERK1/2. (A) Representative immunoblots show signiﬁcantly
increased expression of p-ERK1/2 upon indicated treatment in a time dependent
manner in wt cells when compared to control. Note a signiﬁcant decrease in p-ERK1/2
at later time points in the presence of SST, EGF and SST+EGF. (B) In cells
monotransfected with SSTR1, displayed time dependent increase in p-ERK1/2
expression levels upon treatments with SST or EGF alone, whereas upon combined
treatment with SST+EGF the expression levels of p-ERK1/2 enhanced in comparison to
basal but without any discernable changes at all time points (5–40 min). The
expression of p-ERK1/2 in comparison to the 0 time point remained sustained at all
time points with indicated treatment. In cotransfected cells, however, the p-ERK1/2
levels were sustained at all time points and indicated treatments when compared to 0
time point which was signiﬁcantly less in comparison towt and SSTR1monotransfected
cells (C). The expression levels of ERK1/2 were quantiﬁed using densitometric analyses
as illustrated by the bar graphs. The data presented here is a representation mean±
SEM of three replicate experiments. *Pb0.05 vs. 0 time point; #Pb0.05, treatments ofwt
vs. SSTR1 or SSTR1/5.
Fig. 6. The presence of SSTRs modulates EGF mediated ERK5 phosphorylation. wt and
cells transfected with SSTR1 or SSTR1/5 were treated with SST (1 μM) or EGF (1 nM)
and SST+EGF for indicated time points at 37 °C. Protein (15 μg) was subjected to
Western blot analysis and probed for phospho- and total ERK5 (1:1000). (A) p-ERK5
increased at early time points but gradually decreased in wt cells upon treatment with
SST, EGF and SST+EGF at the later points. (B) In comparison to wt cells, p-ERK5
expression in cells transfected with SSTR1 signiﬁcantly decreased in the presence of SST
and SST+EGF. However, p-ERK5 remained comparable to 0 time point upon EGF
treatment (B). (C) Conversely, in SSTR1/5 cotransfected cells, the phosphorylation of
ERK5 was elevated in time dependent manner upon SST treatment. p-ERK5 remained
signiﬁcantly enhanced upon EGF treatment alone in comparison to control except at
40 min, whereas in combination with SST+EGF, p-ERK expression levels were
comparable to control. Changes in ERK5 expression were quantiﬁed using densito-
metric analyses as illustrated by the bar graphs. *Pb0.05 indicates signiﬁcance when
compared to 0 time points. The signiﬁcant differences between treatments of wt and
SSTR1 or SSTR1/5 transfected cells were indicated by #Pb0.05. Results are expressed as
mean±SEM for three independent experiments.
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Fig. 7. EGF stimulated PI3K cell survival pathway is inhibited in cell expressing SSTR1
and SSTR1/5. wt and cells transfected with SSTR1 or SSTR1/5 were treated and
subjected toWestern blot analysis for phospho- and total PI3K as described inMaterials
and methods. In wt cells, the status of phosphorylated PI3K signiﬁcantly enhanced in
the presence of EGF alone or in combination with SST time dependently. In comparison,
SST alone also increased p-PI3K but not signiﬁcantly different from the control. These
results indicate that in wt cells EGF effect was predominant (A). As depicted in panels B
and C the status of phosphorylated PI3K was relatively less than the control but was
signiﬁcantly diminished when compared to wt cells. Histograms illustrate densitomet-
ric analysis of PI3K levels when adjusted against β-actin. *Pb0.05 indicates the changes
in time and treatments when compared with 0 time points in respective cell lines. The
signiﬁcant changes between treatments of wt and SSTR1 or SSTR1/5 transfected cells
were represented by #Pb0.05. Results are expressed as mean±SEM, n=3.
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illustrated in Fig. 7A, SST enhanced the phosphorylation of PI3K,
although insigniﬁcant from the control. The predominant effect of EGF
on PI3K activation was demonstrated by a signiﬁcant increase in the
levels of phosphorylation of PI3K upon EGF treatment alone, whereas
upon combined treatment with SST the effect of EGF was reduced
(Fig. 7A). Importantly, EGF mediated enhanced PI3K phosphorylation
observed in wt cells was signiﬁcantly diminished in cells expressing
SSTR1 (Fig. 7B). The levels of PI3K phosphorylation in SSTR1
transfected cells were comparable to control (0 time point) upon
treatment with SST, EGF or SST+EGF (Fig. 7B). Similarly, cotrans-
fected cells expressing SSTR1/5 exhibited no signiﬁcant changes in the
status of p-PI3K upon SST, EGF and SST+EGF treatment (Fig. 7C). The
expression levels of PI3K phosphorylation were signiﬁcantly lower
that wt cells.
In wt cells, the status of p-AKT was elevated upon treatment with
EGF alone at all time points, whereas as SST and SST+EGF were
without any effect and displayed p-AKT expression levels comparable
to control (Fig. 8A). The phosphorylation of AKTwas abrogated in cells
expressing SSTR1 without any discernable changes in presence of SST,
EGF or SST+EGF (Fig. 8B). Conversely, cells expressing SSTR1/5
displayed enhanced AKT phosphorylation upon treatment with
SST, EGF or SST+EGF at all time points when compared to control
without any signiﬁcant effect amongst treatment. These observations
indicate a pronounced inhibitory effect of SSTR activation on EGF
mediated PI3K pathway, whereas a receptor-speciﬁc role on AKT
activation.
3.5. SSTR subtype-speciﬁc modulation of EGF mediated activation of p38
MAPK
The activation of p38 plays an important role as an apoptotic
signaling mediator as well as enhances cell proliferation in cell and
tissue dependent manner. Whether SSTR1 or SSTR1/5 modulates EGF
mediated p38 signals is unknown. As shown in Fig. 9A, inwt cells, SST
treatment exhibited no discernable changes in status of p38
phosphorylation. The levels of p-p38 were signiﬁcantly augmented
with EGF alone and in combination with SST suggesting that, in wt
cells, EGF mediated activation of EGFR enhanced p38 phosphorylation
and may be involved in cell proliferation (Fig. 9A). Cells expressing
SSTR1 displayed p38 phosphorylation comparable to basal condition
when treated with SST alone (Fig. 9B). Most importantly, EGF induced
p38 phosphorylation was completely blocked, while with SST+EGF
treatment, p38 expression was similar to SST alone (Fig. 9B). In
cotransfected cells, treatmentwith SSTwas ineffective to activate p38.
Conversely, p38 phosphorylation was signiﬁcantly enhanced upon
EGF treatment alone and with SST (Fig. 9C). Taken together, these
results suggest that SSTR1 and SSTR1/5 regulate EGF mediated
changes in p38 expression in a receptor-speciﬁc manner.
3.6. Somatostatin induces cytostatic and/or cytotoxic effects in receptor
dependent manner
To investigate the cell response upon adaptation to the changes in
MAPK and PI3K/AKT, the expression levels of cyclin dependent kinase
inhibitor, p27Kip1 and PTP1C as an index to demonstrate whether
SSTRs effect is cytostatic or cytotoxic was determined. As illustrated in
Fig. 10A, p27Kip1 expression was enhanced upon SST treatment,
whereas EGF treatment inhibited p27Kip1 in wt cells supporting EGF
mediated cell proliferation. However, combined treatment with SST
+EGF was comparable to EGF effect (Fig. 10A). In cells expressing
SSTR1, p27Kip1 expression was signiﬁcantly upregulated in the
presence of SST or EGF alone and in combination indicating an anti-
proliferative effect (Fig. 10B). In cotransfected cells, the expression of
p27Kip1 was unaffected and remained comparable in all treatments
without any signiﬁcant difference from control (Fig. 10C). Takentogether these observations indicate that SSTR1 alone but not with
SSTR5 regulates anti-proliferative effect through a cytostatic mode of
action.
Fig. 8. SSTR subtype-speciﬁc effect on EGF mediated AKT phosphorylation. wt and cells
transfected with SSTR1 or SSTR1/5 were treated for indicated time and subjected to
Western blot analysis for phospho- and total AKT as described in Materials and
methods. In wt cells, the levels of p-AKT were comparable to the control in presence of
SST alone as well as in combination with EGF. In comparison, EGF enhanced p-AKT
expression signiﬁcantly at all time points except at 40 min (A). The status of p-AKT
expression seen in wt cells was signiﬁcantly diminished in cell expressing SSTR1
without any discernable changes in presence of indicated treatment and time in
comparison to control (B). In contrast, cells expressing SSTR1/5 displayed enhanced p-
AKT expression upon treatment with SST, EGF or SST+EGF at early time points. The
levels of AKT expression were quantiﬁed using densitometric analysis as illustrated by
the histograms. (*Pb0.05 vs. 0 time point; #Pb0.05, treatments of wt vs. SSTR1 or
SSTR1/5). The data presented here is a representation of mean±SEM, n=3.
Fig. 9. SSTR subtypes inhibit EGF mediated p38 activation in time and receptor-speciﬁc
manner.wt and cell transfectedwith SSTR1 or SSTR1/5were treatedwith SST (1 μM), EGF
(1 nM) and SST+EGF for indicated time points and subjected to Western blot analysis
for phospho- and total p38 as described inMaterials andmethods. Inwt cells, the status of
p-p38was comparable to basal expressionupon SST treatment at all timepoints (A). In the
presence of EGF treatment, p-p38 expression enhanced at 10–40 min without any change
at 5 min. In contrast, upon combined treatment with SST+EGF stimulated p-p38,
gradually decreased time dependently (A). Interestingly, in cells transfected with SSTR1,
the expression of p-p38was elevated but not signiﬁcantly different from control upon SST
treatment. Note the complete loss of p-p38 expression in the presence of EGF, whereas
combined treatment with SST+EGF displayed similar effect as seen in SST treatment
across all timepointswhen adjusted to the total p38 (B). In cells cotransfectedwith SSTR1/
5, SST treatment was ineffective to exhibit p38 phosphorylation. The treatment with EGF
alone and in combination with SST enhanced the expression levels of p-p38 at all time
points when compared to control (C). Note the signiﬁcantly lower expression of p-p38 in
cotransfected cells in comparison to wt. *Pb0.05 represents signiﬁcance when compared
with 0 time points, whereas #Pb0.05 indicates the signiﬁcant differences between
the treatments of wt and SSTR1 or SSTR1/5 transfected cells. Results are represented as
mean±SEM of three independent experiments. ND=not detected.
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Fig. 10. SSTR 1mediated cytostatic effect is changed to cytotoxic in cell cotransfected with SSTR1/5. RepresentativeWestern blot analysis illustrating agonist mediated changes in the
expression of p27Kip1 in wt and cells transfected with SSTR1 or SSTR1/5 (A–C). Cells were starved for 24 h prior to treatment with SST in the presence or absence of EGF for 15 min
37 °C and subjected to Western blot analysis for expression of p27Kip1 as illustrated in Materials and methods. (A) The expression of p27Kip1 signiﬁcantly increased in wt cells upon
treatment with SST indicating inhibition of cell proliferation, whereas EGF alone enhanced p27Kip1 expression but less than SST. These results indicate EGF mediated cell
proliferation. p27Kip1 expression remained similar to control upon combined treatment indicating normal cell proliferation (*Pb0.05 vs. the control). (B) Importantly, in cells
transfected with SSTR1, expression of p27Kip1 signiﬁcantly enhanced upon SST or EGF treatment alone and in combination an indicative of inhibition of cell proliferation (*Pb0.05 vs.
the control). (C) Conversely, in cells cotransfected with SSTR1/5, SST or EGF treatment alone or in combination leads to the inhibition of p27Kip1 expression signiﬁcantly (*Pb0.05 vs.
the control). These results demonstrate that p27Kip1 is not involved in SSTR5 mediated inhibition of cell proliferation. (D–F) Western blots depicting SST and EGF mediated changes
in the expression of PTP1C in membrane and cytosolic preparations from wt and cells transfected with SSTR1 or SSTR1/5. In wt cells, the expression of PTP1C in cytosolic as well as
membrane fractions remained unchanged upon indicated treatments (D). In SSTR1 transfected cells, cytosolic PTP1C expression increased signiﬁcantly upon treatment with EGF
alone or in combination with SST, whereas SST effect was comparable to control. However, PTP1C membrane expression was signiﬁcantly increased upon all treatments as indicated
(*Pb0.05 vs. control of respective cellular fraction) (E). As shown in panel F, in comparison cells cotransfected with SSTR1/5, the expression of PTP1C in cytosolic fraction remained
unaltered across all indicated treatments, whereas PTP1C membrane expression signiﬁcantly enhanced upon SST, EGF and SST+EGF treatment (*Pb0.05 vs. control). Bar graphs
represent the quantiﬁcation by densitometric analysis. Results are presented as mean±SEM, n=3.
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translocation. To further elucidate whether apoptosis was involved in
SSTR mediated inhibition of PI3K and associated with increased
expression of p27Kip1, PTP1C membrane translocation was deter-
mined. As illustrated in Fig. 10D, wt cells showed no discernable
changes in PTP1C expression in the membrane as well as cytosolic cell
fractions. In contrast, cells expressing SSTR1 displayed signiﬁcantly
elevated membrane expression of PTP1C following treatments with
SST and EGF alone or in combination (Fig. 10E). The cytosolic
expression of PTP1C, however, remained unchanged with SST alone
but enhanced upon treatments with EGF and SST+EGF (Fig. 10E).
Interestingly, in cotransfected cells, the expression of PTP1C in cytosol
did not change upon any treatment. However, in membrane fractions
enhanced expression was observed upon SST, EGF as well as SST+
EGF treatments, suggesting the translocation of PTPIC from the
cytosol to the membrane (Fig. 10F). These data implicate that SSTR1
and SSTR5 induce opposing effects in these cells, thereby promoting
cell cycle arrest.3.7. AG1478 antagonizes EGFR and potentiates SSTRs mediated signaling
pathways
To ascertain whether the changes mediated by EGF upon EGFR
phosphorylation, MAPKs and PI3K pathways in cells transfected with
SSTR1 or SSTR1/5 are a result of EGFR inactivation by SSTRs, we studied
the effects of EGFR selective antagonist AG1478 on the MAPK and cell
survival signaling. As illustrated in Fig. 11, in wt cells, AG1478
signiﬁcantly inhibited EGF induced EGFR phosphorylation (N3 fold)
along with total EGFR expression. Most importantly, the phosphoryla-
tion of EGFR was completely abolished and not detected in cells
transfected with SSTR1 or SSTR1/5 in treatment speciﬁc manner as
indicated (Fig. 11, Supplementary Fig. S1). EGF enhanced ERK1/2
phosphorylation in wt cells which was signiﬁcantly inhibited in
combined treatment with AG1478, whereas AG1478 alone had no
signiﬁcant effect. In SSTR1 transfected cells, the status of ERK1/2
phosphorylation was signiﬁcantly higher when treated with SST and
SSTR1 speciﬁc agonist L-797,591,whereasexpression levels of p-ERK1/2
Fig. 11. EGFR antagonist AG1478 potentiates the effect of SST on downstream signaling pathways.wt and cells transfected with SSTR1 or SSTR1/5 were treated with SST (1 μM), EGF
(1 nM), L-797,591 or L-817,818 (10nM) in the presence or absence of EGFR antagonist AG1478 (10 nM) for 15 min at 37 °C. Total cell lysate prepared was processed forWestern blot
analysis and probed with speciﬁc phospho- and total antibodies (1:1000). Note the signiﬁcant changes upon treatment with SST and SSTR1 or 5 speciﬁc agonists with or without
EGFR antagonist AG1478. The detailed description of changes in indicated proteins and densitometric analysis is presented in supplementary information (please see Supplementary
Fig. S1 for details).
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treatment with AG1478 alone and in combination with SST, EGF and
SSTR1 speciﬁc agonist the status of p-ERK1/2was comparatively higher
than the control (Fig. 11, Supplementary Fig. S1). In contrast, cells
cotransfected with SSTR1/5 displayed comparable levels of p-ERK1/2 to
control without any discernable changes upon indicated treatments
(Fig. 11, Supplementary Fig. S1).
Inwt cells, treatment with AG1478 alone or with EGF enhanced the
phosphorylation of ERK5, an effect opposite to that seen with ERK1/2
activation. However, EGF effect on p-ERK5 was comparable to the
control. In cells transfected with SSTR1, the expression levels of p-ERK5
were comparable to control upon treatment with SST and L-797,591
alone. In comparison, AG1478 in combination with SST, EGF and SSTR1
speciﬁc agonist L-797,591 resulted in enhanced expression of p-ERK5 in
cells expressing SSTR1. Furthermore, in cells expressing SSTR1/5 the
status of p-ERK5 was enhanced in presence of SST and receptor speciﬁc
agonist alone or in combinationwith AG1478. In comparison, EGF effect
with or without AG1478 was comparable (Fig. 11, Supplementary
Fig. S1).
EGF and AG1478 alone induced activation of p38 in wt cells.
However, combined treatmentof EGFwithAG1478decreased the status
of p-p38 andwas comparable to control (Fig. 11, Supplementary Fig. S1).
In SSTR1 transfected cells, the levels of p-p38 expression in presence of
SST and L-797,591 decreased signiﬁcantly when compared to control.
Importantly, EGF stimulated effect on p-p38 was diminished when
compared to wt cells. However, AG1478 enhanced p-p38 expression
whencombinedwithEGF, SSTand L-797,591 and remainedenhanced in
comparison to the control without any signiﬁcant changes. Conversely,
in cotransfected cells, SST and EGF had no effect on p-p38 expression,
whereas SSTR1 speciﬁc agonist L-797,591 signiﬁcantly enhanced p38
phosphorylation, the effect which was reversed in the combinedtreatment with AG1478. Similarly, AG1478 in combination with SST
signiﬁcantly diminished the p-p38 expressionwhen comparedwith SST
alone. There was no effect on p38 phosphorylation with EGF or SSTR5
speciﬁc agonist L-817,818 alone or in the presence of AG1478,
suggesting predominant role of SSTR1 on p38 pathway in cotransfected
cells (Fig. 11, Supplementary Fig. S1).
Having seen the signiﬁcant changes in MAPK, we next determined
the status of cell survival pathways including PI3K and AKT. The
expression levels of PI3K phosphorylation in wt cells displayed no
discernable changes upon treatment with AG1478 alone or in
combination with EGF, whereas EGF signiﬁcantly increased p-PI3K
expression. In SSTR1 transfected cells, levels of p-PI3K decreased upon
treatment with SST, EGF or L-797,591 alone. AG1478 alone and in
combination with SST, EGF and SSTR1 speciﬁc agonist inhibits total
PI3K. However, when adjusted with β-actin the levels of p-PI3K were
insigniﬁcantly higher than control. In comparison to the cells
expressing SSTR1, cells cotransfected with SSTR1/5 displayed signif-
icantly diminished PI3K phosphorylation upon treatments with SST
and EGF, whereas the expression levels were not changed in presence
of receptor-speciﬁc agonist when compared to control. AG1478 alone
and in combination with indicated treatment decreased p-PI3K
expression. These data indicate a synergistic effect of SSTR1/5 on
the blockade of PI3K pathway. Interestingly, no signiﬁcant changes
were seen in AKT phosphorylation and expression levels were
comparable to control in all experimental conditions regardless of
the cell type (Fig. 11, Supplementary Fig. S1). These data collectively
suggest that blocking EGFR with speciﬁc agonist AG1478 enhanced
the effect of SSTR1 and SSTR1/5 in a receptor-speciﬁc manner on the
signaling pathways. Densitometric analyses describing the signiﬁcant
changes in all experimental conditions are described in detail in
supplementary information (Supplementary Fig. S1).
1184 G. Kharmate et al. / Biochimica et Biophysica Acta 1813 (2011) 1172–11893.8. EGFR knockdown with siRNA enhance SSTR mediated
anti-proliferative effect
To further conﬁrm the changes in MAPK and cell survival pathway
observed with EGFR selective antagonist AG1478, we next introduced
EGFR siRNA in wt and cells stably transfected with SSTR1 or SSTR1/5.
siRNA not only suppressed the basal expression levels of EGFR but also
inhibited MAPK and cell survival pathways and potentiated the effect
mediated by SST. As shown in Fig. 12, an effective blockade of EGFR
with siRNA treatment resulted in efﬁcient (N80%) loss of EGFR
expression and phosphorylation in wt cells. Most importantly, in cells
transfected with SSTR1 and SSTR1/5, EGFR phosphorylation was
completely abrogated upon treatments with SST, EGF as well as SSTR1
and SSTR5 speciﬁc agonist L-797,591 or L-817,818, respectively.
Furthermore, ERK1/2 phosphorylation in wt and cells expressing
SSTR1 remained unchanged upon agonist treatments in the presence
of EGFR siRNA. Conversely, in cotransfected cells the phosphorylation
of ERK1/2 was signiﬁcantly higher upon SST, SST+EGF and SSTR5
speciﬁc agonist L-817,818 in the presence of siRNA. However, EGF and
SSTR1 speciﬁc agonist L-797,591 failed to exert any effect on ERK1/2
phosphorylation in cells infected with siRNA, suggesting a SSTR5
predominant effect in modulating ERK1/2 (Fig. 12, Supplementary
Fig. S2).
We next determined whether the status of p38 phosphorylation is
affected upon knocking down of EGFR. As depicted in Fig. 12, EGF
enhanced p38 phosphorylation in wt cells despite EGFR knockdown.
In comparison, cells expressing SSTR1 displayed enhanced but
insigniﬁcant p38 phosphorylation upon indicated treatments in cells
infected with EGFR siRNA. In cells cotransfected with SSTR1/5, the
knockdown of EGFR led to the inhibition of p38 phosphorylation that
was signiﬁcant and pronounced when treated with EGF and SSTR1
speciﬁc agonist L-797,591. However, SST and SSTR5 speciﬁc agonist L-
817,818 was without any effect and p-p38 expression remained
comparable to the control (−siRNA). Consistent with the changes inFig. 12. SSTRs subtype-speciﬁc role on downstream signaling pathways upon knockdown of
siRNA (2 μg) for 36 h at 37 °C. Subsequently, the cells were treated with SST (1 μM) with or
respectively, for 15 min at 37 °C. The whole cell extracts were subjected to Western blot a
(1:1000) as per details in Materials and methods. Importantly, the p-EGFR was completely ab
down EGFR substantiated the effects of SST via SSTRs in a subtype-speciﬁc manner and rever
description of changes and densitometric analysis is presented as supplementary informatip27Kip1 and PTP1C expression these results support cytostatic effect of
SSTR1.
EGFmediated PI3K phosphorylationwas diminished following EGFR
knockdown inwt cells.Moreover, EGFR knockdown exhibited complete
inhibition of PI3K phosphorylation in cells transfected with SSTR1 or
SSTR1/5 upon agonist treatments, suggesting that the effect of SSTRs
was potentiated in the absence of EGFR (Fig. 12, Supplementary Fig. S2).
In wt cells, the phosphorylation of AKT remained unchanged despite
siRNA infection. Importantly, AKT phosphorylation was completely
abolished in cells transfected with SSTR1 and SSTR1/5 upon EGFR
knockdown (Fig. 12, Supplementary Fig. S2). Cells transfected with
mismatched siRNAnot relatedwith the sequence of any genewere used
as a negative control (data not shown). Taken together, these results
suggest that a lack/inhibition of EGFRmight improve the effect of SST to
regulate cell proliferation and signaling cascades. Densitometric
analyses describing the signiﬁcant changes in all experimental condi-
tions are presented in detail (Supplementary Fig. S2).3.9. Heterodimerization between SSTR1/EGFR impedes EGFR/ErbB2
heteromeric complex formation in SSTR1 transfected cells
To decipher the molecular mechanism involved, we ﬁrst deter-
mined the expression of ErbB2, SSTR1 and SSTR5 in EGFR immuno-
precipitate prepared from wt and cells transfected with SSTR1 or
SSTR1/5. Inwt cells, EGFR and ErbB2 exist as preformed heterodimers
which was further signiﬁcantly enhanced upon treatment with EGF
(Fig. 13A). The formation of heteromeric complex was further
conﬁrmed using microscopic pbFRET analysis as described in Material
and methods. As illustrated in Fig. 13B and Table 1, in the basal state
EGFR and ErbB2 exist as preformed heterodimers showing an effective
FRET efﬁciency of 23.1±2.3% which was enhanced upon treatment
with EGF and displayed FRET efﬁciency of 35.2±1.4%, suggesting the
role of EGFR activation in heterodimerization.EGFR. wt and cells expressing SSTR1 or SSTR1/5 were transfected transiently with EGFR
without EGF (1 nM) SSTR1 or SSTR5 speciﬁc agonists L-797,591 or L-817,818 (10 nM),
nalysis using phospho- and total EGFR, ERK1/2, p38, PI3K and AKT speciﬁc antibodies
olished in cells transfected with SSTR1 or SSTR1/5 when compared towt cells. Knocking
sed the EGF mediated effects on the key downstream signaling pathways. The thorough
on (Supplementary Fig. 2).
Fig. 13. The dissociation of EGFR/ErbB2 heterodimeric complex in the presence of
SSTR1. Co-immunoprecipitation and pbFRET analysis were performed in wt and cells
transfected with SSTR1 to determine the heterodimerization as described in Materials
and methods. (A) In wt cells, the expression of ErbB2 in EGFR immunoprecipitate
displayed heterodimerization between EGFR/ErbB2 in basal condition which further
enhanced upon EGF treatment. Histogram represents the relative FRET efﬁciency
between EGFR/ErbB2 in wt cells. The relative FRET efﬁciency between EGFR/ErbB2 was
signiﬁcantly increased upon EGF treatment when compared to the control cells indicate
strengthening of complex formation between EGFR/ErbB2 (*, Pb0.05 vs. control) (B).
(C) In cells transfected with SSTR1, EGFR immunoprecipitate displayed expression of
SSTR1 suggesting preformed heterodimers of SSTR1/EGFR in basal conditions which
enhanced upon SST treatment. Note the decrease in formation of heteromeric complex
upon treatment with EGF alone or in combination with SST. (D) The speciﬁcity of co-
immunoprecipitation was conﬁrmed in EGFR immunoprecipitate prepared from wt
cells and immunoblotted for HA antibodies for SSTR1 expression. (E) Histograms
represent signiﬁcant changes in the relative FRET efﬁciencies between SSTR1/EGFR
(open bar) and EGFR/ErbB2 (hatched bar) in cells expressing SSTR1. Consistent with co-
IP, the relative FRET efﬁciency between SSTR1/EGFR was augmented with SST
treatment alone but was signiﬁcantly diminished upon EGF treatment alone or in
combination with SST. Note the signiﬁcant loss in relative FRET efﬁciency between
EGFR/ErbB2 across all treatments in the presence of SSTR1 (#Pb0.05, SSTR1/EGFR
heterodimerization vs. control). Results are presented as mean±SEM of 3 independent
experiments performed in duplicate (total number of 60–70 cells were analyzed per
treatment). Data were analyzed using two-way ANOVA and Bonferroni's post-test was
applied to compare with control.
Table 1
Agonist dependent heterodimerization between EGFR and ErbB2 in wt cells (A) and
dissociation in cells transfected with SSTR1 (B).
Treatment τavg %E n
A.
EGFR + ErbB2
Control D−A 17.5±1.41 63
D+A 22.8±3.4 23.1±2.3 65
EGF (1 nM) D+A 27.14±1.4 35.2±1.4* 60
B.
SSTR1 + EGFR
Control D−A 21.8±2.0 68
D+A 28.04±1.3 22.2±1.7 65
SST (1 μM) D+A 28.6±3.5 23.9±2.8 60
EGF (1 nM) D+A 24.8±3.1 12.1±2.5# 62
SST+EGF D+A 26.6±1.8 18.32±1.9# 64
EGFR+ErbB2
Control D−A 25.2±1.5 70
D+A 24.9±1.3 ND 68
SST (1 μM) D+A 24.4±1.4 ND 64
EGF (1 nM) D+A 25.2±2.0 ND 65
SST+EGF D+A 25.6±1.9 ND 61
D−A and D+A correspond to donor in the absence and presence of an acceptor,
respectively. τavg, mean of n photobleaching time constants; E, average effective FRET
efﬁciency; n, number of cells analyzed. Means are expressed as ±SE and data are
representation of three independent experiments. *Pb0.05 EGFR/ErbB2 vs. control;
#Pb0.05, SSTR1/EGFR heterodimerization vs. control. FRET efﬁciency lower than 3.5%
was considered as not detected (ND).
1185G. Kharmate et al. / Biochimica et Biophysica Acta 1813 (2011) 1172–1189In cells transfected with SSTR1, the expression of SSTR1 in EGFR
immunoprecipitate suggested preformed heterodimers of SSTR1/
EGFR in basal conditions which enhanced upon SST treatment.
However, the formation of heteromeric complex decreased upon
treatment with EGF alone or in combination with SST and indicates
the dissociation of SSTR1/EGFR complex (Fig. 13C). To determine the
speciﬁcity of heterodimerization between SSTR1/EGFR, co-IP was
conﬁrmed in EGFR immunoprecipitate prepared from wt cells and
immunoblotted with anti-HA antibody for expression of SSTR1
(Fig. 13D). In support to co-IP, pbFRET analysis was performed in
cells expressing SSTR1. As illustrated in Fig. 13 E, the heterodimeriza-
tion between EGFR/ErbB2 was completely diminished without any
discernable effect of SST or EGF treatment (Fig. 13E). The dissociation
of EGFR/ErbB2 was accompanied with the formation of the hetero-
meric complex between SSTR1/EGFR with relative FRET efﬁciency of
22.2±1.7% in basal condition. The relative effective FRET efﬁciency
was further increased to 23.9±2.8% upon SST treatment, thus
strengthening the heteromeric complex. Importantly, in the presence
of EGF, FRET efﬁciency was signiﬁcantly decreased to 12.1±2.5%. Incombined treatment with SST+EGF, relative FRET efﬁciency was
reduced to 18.3±1.9% when compared with control (Fig. 13E and
Table 1).
3.10. SSTR1 and SSTR5 exhibit receptor-speciﬁc heterodimerization with
EGFR and impede EGFR/ErbB2 heterodimerization in SSTR1/5
cotransfected cells
Having seen the crucial role of SSTR1 in dissociation of EGFR/ErbB2
complex in monotransfected cells, we next sought to determine
whether the presence of SSTR1/5 also impedes heterodimerization
between EGFR/ErbB2. Cells cotransfected with SSTR1/5 were pro-
cessed for co-IP and microscopic pbFRET analysis. As shown in
Fig. 14A–C, EGFR immunoprecipitate prepared from cells infected
with SSTR1/5 was probed with anti-HA (SSTR1) or anti-cMyc (SSTR5)
antibodies. SSTR1 was highly expressed in EGFR immunoprecipitate
in basal condition and decreased upon treatment with SST alone.
However, the SSTR1 expression was similar to the control when
treated with EGF alone or in combination with SST at the expected
molecular size of N232 kDa (Fig. 14A). EGFR immunoprecipitate also
displayed enhanced SSTR5 expression upon SST treatment alone or in
combination with EGF when compared to control. These results
indicate the complex formation between SSTR5/EGFR. Conversely, the
expression of this complex was decreased upon treatment with EGF
alone (Fig. 14B). The speciﬁcity of co-immunoprecipitation was
conﬁrmed in EGFR immunoprecipitate prepared from wt cells and
immunoblotted for cMyc antibody for SSTR5 expression (Fig. 14C).
As shown in Fig. 14D and Table 2, pbFRET analysis in cells
cotransfected with SSTR1/5 revealed receptor and treatment speciﬁc
heterodimerization between SSTR1 and SSTR5 with EGFR and led to
the dissociation of EGFR/ErbB2 complex. SSTR1 and EGFR exist as
heterodimers in basal condition and exhibited relative FRET efﬁciency
of 8.31±1.7% which was considerably decreased to 1.6±1.2% upon
SST treatment. SSTR1/EGFR heterodimerization seen in cotransfected
cells was signiﬁcantly decreased in comparison to the monotrans-
fected cells expressing SSTR1. The FRET efﬁciency between SSTR1/
EGFR upon EGF treatment alone was 6.7±2.5% lower than control. In
comparison upon combined treatment with SST+EGF, FRET
Fig. 14. SSTRs impede EGFR and ErbB2 heterodimerization. Co-immunoprecipitation
and pbFRET analysis were performed in cells cotransfected with SSTR1/5 to determine
the heterodimerization as described in Materials and methods. (A) The expression of
SSTR1 (detected using anti-HA antibody) in EGFR immunoprecipitate prepared from
cotransfected cells illustrate agonist dependent heterodimerization between SSTR1/
EGFR. Note high expression of SSTR1 in EGFR immunoprecipitate in basal conditions
which decreased upon treatment with SST alone. However, the receptor expression was
comparable to the control when treated with EGF alone or in combination with SST (A).
SSTR5 expression in EGFR immunoprecipitate was enhanced upon SST treatment alone
and in combination with EGF when compared to control, suggesting complex formation
between SSTR5/EGFR. Conversely, the expression of such complex was diminished
upon treatment with EGF (B). The speciﬁcity of co-immunoprecipitation was conﬁrmed
in EGFR immunoprecipitate prepared from wt cells and immunoblotted for cMyc
antibodies for SSTR5 expression. (C). (D) Histograms illustrating agonist and receptor-
speciﬁc changes in the relative FRET efﬁciencies between EGFR/SSTR1 (open bar),
SSTR5/EGFR (solid bar) and EGFR/ErbB2 (hatched bar). Note signiﬁcant decrease in
FRET efﬁciency upon treatment with SST or SSTR1 speciﬁc agonist L-797,591 alone or
when combined with EGF when compared to control indicating the loss of EGFR/SSTR1
heterodimerization. The FRET efﬁciency between SSTR1/EGFR was comparable to basal
upon treatment with EGF and SST+EGF (#Pb0.05, SSTR1/EGFR heterodimerization vs.
control) (D). Conversely, FRET efﬁciencies between SSTR5/EGFR signiﬁcantly enhanced
upon all treatments except EGF alone which was comparable to the basal suggesting
strong heterodimerization between SSTR5/EGFR upon SSTR5 activation ($Pb0.05,
SSTR5/EGFR heterodimerization vs. control). The FRET efﬁciency between EGFR/ErbB2
is signiﬁcantly decreased indicating loss of complex formation between EGFR/ErbB2 in
the presence of SSTR1/5. These observations indicate dissociation of EGFR/ErbB2
complex and SSTR subtype-speciﬁc association with EGFR. Results are expressed as
mean±SEM of 3 independent experiments done in duplicate (total number of 60–70
cells were analyzed per condition). Data were analyzed using two-way ANOVA and
Bonferroni's post-test was applied to compare with control.
Table 2
Receptor-speciﬁc heterodimerization between SSTR1 and SSTR5 with EGFR and
dissociation of heteromeric complex between EGFR/ErbB2 in HEK293 cells cotrans-
fected with SSTR1/5.
Treatment τavg %E n
SSTR1 + EGFR
Control D−A 21.8±1.0 66
D+A 25.99±0.9 8.31±1.7 63
SST (1 μM) D+A 24.2±2.4 1.6±1.2# 61
EGF (1 nM) D+A 25.5±1.4 6.7±2.5 62
SST+EGF D+A 26.76±1.1 10.9±1.9 61
L-797,591 D+A 23.6±1.4 ND 68
L-797,591+EGF D+A 22.1±1.6 ND 60
SSTR5+EGFR
Control D−A 18.7±1.5 65
D+A 20.9±1.7 10.5±1.5 65
SST (1 μM) D+A 25.7±0.9 27.2±1.2$ 61
EGF (1 nM) D+A 20.8±0.7 10.4±1.1 69
SST+EGF D+A 28.2±0.5 25.4±2.0$ 62
L-817,818 D+A 29.4±2.5 33.2±1.3$ 62
L-817,818+EGF D+A 29.4±1.2 36.3±1.3$ 66
EGFR+ErbB2
Control D−A 23.2 61
D+A 23.0±2.0 ND 67
SST (1 μM) D+A 23.8±2.2 ND 67
EGF (1 nM) D+A 24.5±2.1 ND 64
SST+EGF D+A 22.8±2.2 ND 68
D−A and D+A represent the donor in the absence and presence of an acceptor,
respectively. τavg, mean of n photobleaching time constants; E, average effective FRET
efﬁciency; n, number of cells analyzed. Means are expressed as ±SE and data are
representation of three independent experiments. #P b0.05, SSTR1/EGFR
heterodimerization vs. control; $Pb0.05, SSTR5/EGFR heterodimerization vs. control.
FRET efﬁciency lower than 3.5% was considered as not detected (ND).
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Additionally, we also observed total loss of FRET efﬁciency and
heterodimerization between SSTR1/EGFR upon treatment with SSTR1
speciﬁc agonist L-797,591, alone and in combination with EGF.
The cells expressing SSTR1/5 exhibited effective FRET efﬁciency of
10.5±1.5% between SSTR5/EGFR in control. Furthermore, the
heterodimerization between SSTR5/EGFR was augmented upon treat-
ment with SST and displayed effective FRET efﬁciency of 27.2±1.2%.
The FRET efﬁciency of 10.4±1.1% between SSTR5/EGFR observed in
presence of EGF was comparable to control. In contrast, combined
treatment with SST+EGF resulted in enhanced FRET efﬁciency of
25.4±2.0%. Surprisingly, there was relatively higher FRET efﬁciency
of 33.2±1.3% and 36.3±1.3% upon treatment with SSTR5 speciﬁc
agonist alone and with EGF, respectively, indicating the stabilization
of heteromeric complex between SSTR5/EGFR (Fig. 14D and Table 2).These results support the predominant role of SSTR5 in heterodimer-
ization. Furthermore, EGFR/ErbB2 heterodimerization in the control
as well as upon indicated treatment was signiﬁcantly diminished
suggesting that the presence of both SSTR1 and 5 leads to the
dissociation of the EGFR/ErbB2 complex. Taken together, our data
analyzing protein–protein interactions revealed that SSTR subtypes
potentially impede ErbBs heterodimerization. Moreover, the func-
tional consequences of the dissociation of ErbBs complex might be
responsible for the changes seen in the signaling pathways described
above.4. Discussion
The opposing effects of EGF and SST on cell proliferation are well
established and have been potential clinical targets to suppress the
tumor progression of different origins. Despite extensive studies, the
role of EGFR and SSTR subtypes in tumor biology remains elusive. We
have recently shown that SSTR5 impedes EGFR/ErbB2 heterodimer-
ization andmodulates EGF mediated downstream signaling pathways
[46]. In extension to these results, in this report we demonstrate that
the presence of SSTR1 and SSTR1/5 negatively modulates EGF
mediated changes in MAPK and cell survival pathways. Whether
SSTR subtypes functionally interact with ErbBs in receptor-speciﬁc
manner is unknown. SSTRs inhibit EGF mediated phosphorylation of
EGFR in comparison to the cells lacking SSTRs and exert changes in the
status of ERK5, p38 and inhibit PI3K/AKT cell survival pathway.
Concomitantly, the use of EGFR antagonist and siRNA supports SSTR
subtypes mediated changes in signaling pathways. We provide ﬁrst
comprehensive description and compelling evidence that SSTR in
addition to inhibit cell survival signaling cascades also impedes EGFR/
ErbB2 heterodimerization in receptor-speciﬁc manner. The dissocia-
tion of ErbBs complexes might serve as novel mechanism in
regulation of EGF mediated signaling pathways attributed to tumor
growth and poor prognosis provided if proven in tumor cells.
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membrane upon agonist treatment [45]. Furthermore, lesser degree of
colocalization between EGFR/ErbB2 was observed in SSTR1 mono-
transfected cells in comparison to cotransfected cells possibly
attributed with SSTR1 upregulation at cell surface. SSTR1 membrane
expression in cotransfected cells might be associated with SSTR5
internalization as described earlier [25]. The changes in cell surface
expression and colocalization of EGFR and ErbB2 in wt cells in
comparison to cells transfected with SSTR1 or SSTR1/5 associate with
the receptor phosphorylation and modulation of signaling cascades.
Importantly, receptor-speciﬁc trafﬁcking upon agonist activation
functionally associates with receptor interaction at cell surface.
Consistent with previous observations the level of EGFR expression
and the duration of EGFR phosphorylation are associated with tumor
progression. The inhibition of EGFR phosphorylation could possibly be
the ﬁrst step in the intervention of cell growth and signiﬁcant
therapeutic target in tumors of various origins. Based on this notion,
the presence of SSTR1 and SSTR1/5 inhibits EGFR phosphorylation and
asserts the role of SSTRs in this respect. Transactivation of RTKs via
GPCRS in modulation of MAPK signaling is a well documented concept
[36]. In agreement with these observations, EGF enhanced p-ERK1/2 in
wt cells, suggesting that EGF transduced cell proliferative signals via ERK
activation [53,55,56]. Like EGFR, SSTRs also activate ERK1/2 phosphor-
ylation and inhibit cell proliferation in receptor and cell speciﬁcmanner
[29,44]. In wt cells, SST activates ERK1/2 phosphorylation possibly via
pertussis toxin (PTX) insensitive pathway since this effect is blocked
partially in the presence of PTX. Furthermore, it has been shown
previously that HEK293 cells also expressed relatively low amounts of
SSTR2 endogenously [57]. The enhanced phosphorylation observed in
presence of EGFwas also sensitive to PTX treatment as described earlier
[58]. This is in agreement with previous studies indicating that HEK293
cells are PTX sensitive or insensitive in activation of ERK1/2 in presence
of endogenous LPA, endothelin and thrombin receptor [58]. These
observations strongly support the hypothesis that Gi and Gq11 coupled
receptors utilize the Gα and Gβγ subunits of G-protein to activate ERK1/
2 phosphorylation [59,60]. The opposing effects of EGFR and SSTR
subtypes are further supported by our data presented in Fig. 5A
indicating that both EGF and SST activate ERK1/2. Florio et al. reported
that in CHO-K1 cells, SST activates MAPK as well as potentiates bFGF-
induced phosphorylation of ERK1 via SSTR1 [29,44]. Remarkably,
consistent with these observations, our data showed that activation of
SSTR1 enables more efﬁcient activation of ERK1/2 upon treatment with
SST alone or with EGF. In cells transfected with SSTR1/5, ERK1/2
expression increases upon treatmentwith SST albeit to the lesser degree
in comparison to SSTR1 monotransfected cells. These results are
consistent with our recent studies on SSTR5 supporting the predomi-
nant effect of SSTR5 in cotransfected cells [46]. Taken together these
results indicate different physiological response of cells with activated
ERK.
Cell proliferation, speciﬁcally in cancer cells, can be inhibited by
blocking ERK5 activation [52]. The activation of ERK5 recruits Grb2/
SOS complex upon EGFR transactivation [53]. In agreement with these
studies, inhibition of EGF mediated ERK5 activation in the presence of
SSTR subtypes may anticipate the blockade of Grb2/SOS complex
formation. We have recently shown that in MCF-7 and MDA-MB-231
breast cancer cells, SSTR1 and 5 regulate these adaptor proteins in cell
speciﬁc manner and this effect was dependent on the status of
estrogen receptor and EGFR expression [23]. Whether this association
in non-tumor cells exists needs to be determined and cannot be ruled
out from the discussion.
In wt cells, the presence of EGF increased p38 phosphorylation,
suggesting that p38 is involved in EGF mediated cell proliferation and
promoting tumor progression. These data are further supported by
loss of EGF activated p38 in cells monotransfected with SSTR1,
suggesting a potential anti-proliferative role of SSTR1 subtypes via
inhibition of p38, although cells cotransfected with SSTR1/5 exhibitloss of p-p38 levels with SST. However, increased p38 phosphoryla-
tion in the presence of EGF alone or in combination with SST could be
cytostatic. This supposition is further supported by the loss of EGF
effect at the later time point and conversely sustained in combination
with SST. In addition, the PI3K pathway is stimulated by various
growth factors which results in abnormal cell growth contributing to
tumor progression and resistance to hormonal therapy. Inhibition of
PI3K/AKT pathway is therefore attractive therapeutic target for
cancers [61]. Rexer et al. demonstrated that to exert anti-tumor
effect, the selective inhibitors of EGFR and ErbB2 should have an
ability to inhibit PI3K/AKT [42,62]. In agreement with these observa-
tions, we demonstrate the inhibition of PI3K/AKT in the presence of
SSTR1 activation. Moreover, this inhibition was more pronounced in
the presence of SSTR1/5, suggesting that SSTR activation might play a
role in response to trastuzumab treatment in cancer. Furthermore, the
inhibition of PI3K also leads to the blockade of AKT phosphorylation in
the presence of SSTR1 and remains unchanged in SSTR1/5 cells. It is
highly possible that the gradual loss of SSTR subtypes as the tumor
progresses might, in part, be responsible for the loss of trastuzumab
responsiveness being associated with enhanced PI3K and loss of PTEN
[43].
In support to the suppression of p38 and PI3K/AKT pathways, our
ﬁndings show parallel changes in the index of cell proliferation, p27Kip1
expression and PTP membrane translocation. In accordance with
previous observations, activation of p27Kip1 and membrane transloca-
tion of PTP from the cytosol to the membrane is associated with SST
induced anti-proliferative effect via two different mechanism, i.e.,
cytostatic or cytotoxic. The enhanced p27Kip1 expression and PTP
membrane translocation strongly support the functional consequence
of PI3K inhibition in the presence of SSTRs [63,64]. However, EGF
stimulated PTP in membrane fraction might be associated with
dephosphorylation of EGFR and consequently the modulation of other
signaling pathways [65]. Taken together these results suggest a
cytostatic effect of SSTR subtypes as described earlier [66].
To ascertain that EGF stimulated EGFR involved in activation of
signaling cascades we used EGFR inhibitor AG1478. Previous studies
have shown that AG1478 is an effective suppressor of EGFR mediated
cell proliferation [67,68]. Similarly, we here describe that AG1478
blocked the effects of EGFR and enhanced the effects of SSTR1 and
SSTR1/5 on ERK1/2 and ERK5 phosphorylation along with p38 and
consequently resulted in inhibition of PI3K/AKT cell survival pathway
in a receptor-speciﬁc manner. These observations are further
conﬁrmed by blocking EGFR using siRNA in knockdown experiments.
Our data additionally revealed that EGFR regulates MAPK pathway
independent to cell survival pathway. Importantly, cell survival
pathways including PI3K/AKT are two independent signaling cascades
regulated differently. These data anticipate that the blockade of ErbBs
is the prerequisite for the beneﬁcial effect of SST treatment in ErbB
positive tumors of different origins.
The complexity in MAPK and PI3K/AKT pathways anticipate
further studies to elucidate the exact molecular mechanism for the
role of SSTR subtypes. Consistent with previous studies, we observed
constitutive and EGF mediated formation of EGFR/ErbB2 heterodi-
mers in wt cells [69,70]. Whether SSTR subtypes impedes ErbBs
homo- and heterodimerization has not been explored in detail. Our
recent study has shown that SSTR5 dissociated the heteromeric
complex between EGFR/ErbB2 [46]. Here we provide the additional
evidence that SSTR1 and SSTR1/5 also interfere with the formation of
heteromeric complex between ErbB subtypes in a receptor-speciﬁc
manner. In the presence of SSTR1, cells exhibit the formation of
heteromeric complex between SSTR1/EGFR and subsequently lead to
the dissociation of EGFR/ErbB2 heterodimerization that possibly
resulted in the inhibition of EGFR phosphorylation. Most importantly,
cells coexpressing SSTR1/5 respond differently than the monotrans-
fected cells. Cotransfected cells showed heterodimerization between
SSTR5/EGFR with the dissociation of SSTR1/EGFR and EGFR/ErbB2
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may also form heteromeric complex between SSTR1/5 upon SST or
receptor-speciﬁc agonist treatment and cannot be excluded from
discussion [25].
Hereweproposed that potential interference of SSTRs in EGFR homo-
and/or heterodimerization may serve as a regulatory mechanism for the
role of SSTR subtypes in the modulation of mitogenic effects. Such
speculation is in general agreement to previous studieswhere it has been
demonstrated that the presence of ErbB2 and ErbB3 impedes the
internalization of EGFR and resulted in EGFR phosphorylation due to
prolongmembraneexpression [71]. In suchconditions, EGFRdegradation
is reduced and resulted in enhanced signaling due to the formation of a
heteromeric complex with EGFR and accounts for signaling modulation
[51]. Most signiﬁcantly, EGFR homodimerization is most effective in
inducing EGFR phosphorylation in the presence of EGF than the
heterodimerization with ErbB3 following activation by neuregulin [71].
In support of these observations, we have shown that the presence of
SSTRs blocks EGFRhomodimerization aswell as heterodimerizationwith
ErbB2. Taken together our results implicate a competing action of SSTR
subtypes in EGFR dimerization to cause inhibition of EGFR phosphory-
lation and subsequently the modulation of signaling cascades. The
presence of active dimers in the absence of ligand binding has also been
proposed. Moreover, RTK auto-phosphorylation even in the absence of
ligand, receptor over-expression also triggers receptor phosphorylation.
However, we do not exclude the possibility that EGF treatment may also
account for homo- and/or heterodimerization between other ErbBs
involved in themodulation of signaling.Most importantly, the changes in
receptor stoichiometry, conformational dynamics and receptor orienta-
tion at the cell surface, the key regulatory mechanisms for receptor
heterodimerization might play critical role in receptor-speciﬁc manner.
The molecular mechanisms associated with the heterogeneity in
ErbBspositive tumorprogression remain largely obscuredespite several
advances. ErbBs are the prominent regulator of cell proliferation.
Inactivation of ErbBs and the inhibition of tumor regulatory pathways
serve as an instrumental tool in drug design for tumor treatment. In
response to EGF, changes described here are largely associated with the
activation of EGFR because ErbB2 is not activated by EGF unless it is in a
complexwith EGFR, ErbB3 lacks tyrosine kinase domain,whereas Erbb4
is poorly understood. This is the ﬁrst study to provide evidence of
protein–protein interaction which could be used as a therapeutic target
for treatment of cancers involving ErbBs. The loss of EGFR interaction
with ErbB2 or possibly other ErbBs and subsequent inhibition of EGFR
phosphorylation and cell survival pathway provide a novel mechanism
aswell as a previously unidentiﬁed role of SSTR subtypes inmodulation
of EGF effect. Previous studies have shown that heterodimerization
between SSTR5 and dopamine receptor 2 is strongly linked with
implication in pituitary tumor [72]. Further studies are warranted to
elucidatewhether the results described here can be translated in breast,
prostate and pituitary cancer cells involving SSTR and ErbBs as potential
therapeutic target. It is worth investigating whether SSTRs might be
exploited therapeutically in combination with inhibition of ErbBs for
cancer treatment. In conclusion, we provide evidence that ErbB
conformational dynamics and orientation at the cell surface are
interrupted in the presence of SSTR subtypes and serve as a plausible
molecular mechanism for the role of SSTRs to modulate EGF mediated
tumor promoting effects. Taken together, our data revealed unappre-
ciated role of SSTRs that contribute to inhibit EGFR induced changes that
may signiﬁcantly advance our understanding of tumor progression,
patient prognosis and future drug development.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2011.03.006.
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